<DOC>
	<DOC>NCT02627924</DOC>
	<brief_summary>The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Korea</brief_summary>
	<brief_title>Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject has a diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis). Male or female subject ≥18 years of age (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label. Patients with moderate to severe RA defined as Disease Activity Score in 28 Joints (DAS28) (ESR) or DAS28 (CRP) &gt;3.2 Biologically treatment naïve and initiated adalimumab at baseline visit Availability of clinical data of the previous 12 weeks prior to baseline Ability to selfcomplete patient questionnaires Subject must be able and willing to provide written informed consent and comply with the requirements of this study protocol. Patients who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks. Participation in any RArelated clinical trial at the time of enrolment, at baseline or at any point during the past 24 weeks prior to baseline Patients who in the clinician's view, may not be able to accurately report their QoL or prior resource utilization Patients who in the clinician's view, may not be able to adhere to adalimumab therapy over 24 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>patient-reported QoL(Quality of Life)</keyword>
	<keyword>Work productivity</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>